vs
Side-by-side financial comparison of ON24 INC. (ONTF) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $34.6M, roughly 1.7× ON24 INC.). ON24 INC. runs the higher net margin — -18.8% vs -83.0%, a 64.2% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -5.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -4.2%).
ON24 Inc., a San Francisco-based company, is a cloud-based platform that develops and sells web-based webinar, virtual conferencing, content hub, and landing page applications as a service for marketing and sales teams in B2B organizations. In 2023 it expanded its offerings to include generative AI services.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ONTF vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.6M | $57.3M |
| Net Profit | $-6.5M | $-47.5M |
| Gross Margin | 74.9% | 91.6% |
| Operating Margin | -23.5% | -82.2% |
| Net Margin | -18.8% | -83.0% |
| Revenue YoY | -5.6% | 36.9% |
| Net Profit YoY | 26.8% | -9.6% |
| EPS (diluted) | $-0.15 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.6M | $57.3M | ||
| Q3 25 | $34.6M | $51.3M | ||
| Q2 25 | $35.3M | $48.5M | ||
| Q1 25 | $34.7M | $32.7M | ||
| Q4 24 | $36.7M | $41.8M | ||
| Q3 24 | $36.3M | $33.3M | ||
| Q2 24 | $37.3M | $29.1M | ||
| Q1 24 | $37.7M | $26.0M |
| Q4 25 | $-6.5M | $-47.5M | ||
| Q3 25 | $-6.4M | $-52.9M | ||
| Q2 25 | $-7.3M | $-46.6M | ||
| Q1 25 | $-8.7M | $-49.5M | ||
| Q4 24 | $-8.9M | $-43.3M | ||
| Q3 24 | $-11.4M | $-43.6M | ||
| Q2 24 | $-11.2M | $-32.3M | ||
| Q1 24 | $-10.7M | $-141.4M |
| Q4 25 | 74.9% | 91.6% | ||
| Q3 25 | 74.7% | 89.3% | ||
| Q2 25 | 75.1% | 88.6% | ||
| Q1 25 | 73.8% | 88.8% | ||
| Q4 24 | 74.5% | 90.9% | ||
| Q3 24 | 74.3% | 88.5% | ||
| Q2 24 | 74.5% | 89.9% | ||
| Q1 24 | 74.1% | 89.2% |
| Q4 25 | -23.5% | -82.2% | ||
| Q3 25 | -23.1% | -102.6% | ||
| Q2 25 | -26.0% | -93.4% | ||
| Q1 25 | -30.1% | -143.7% | ||
| Q4 24 | -32.1% | -98.6% | ||
| Q3 24 | -36.7% | -132.0% | ||
| Q2 24 | -35.0% | -139.2% | ||
| Q1 24 | -33.1% | -538.7% |
| Q4 25 | -18.8% | -83.0% | ||
| Q3 25 | -18.4% | -103.1% | ||
| Q2 25 | -20.6% | -96.1% | ||
| Q1 25 | -25.1% | -151.4% | ||
| Q4 24 | -24.2% | -103.6% | ||
| Q3 24 | -31.4% | -131.2% | ||
| Q2 24 | -29.9% | -110.9% | ||
| Q1 24 | -28.4% | -544.4% |
| Q4 25 | $-0.15 | $-0.73 | ||
| Q3 25 | $-0.15 | $-0.82 | ||
| Q2 25 | $-0.17 | $-0.75 | ||
| Q1 25 | $-0.21 | $-0.81 | ||
| Q4 24 | $-0.21 | $-0.71 | ||
| Q3 24 | $-0.27 | $-0.73 | ||
| Q2 24 | $-0.27 | $-0.55 | ||
| Q1 24 | $-0.26 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.0M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.4M | $139.1M |
| Total Assets | $228.4M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.0M | $388.9M | ||
| Q3 25 | $47.2M | $416.1M | ||
| Q2 25 | $37.7M | $291.0M | ||
| Q1 25 | $26.8M | $314.5M | ||
| Q4 24 | $14.9M | $320.6M | ||
| Q3 24 | $11.0M | $298.4M | ||
| Q2 24 | $15.5M | $319.1M | ||
| Q1 24 | $18.3M | $201.2M |
| Q4 25 | $139.4M | $139.1M | ||
| Q3 25 | $144.3M | $148.8M | ||
| Q2 25 | $150.0M | $-11.9M | ||
| Q1 25 | $153.7M | $18.9M | ||
| Q4 24 | $159.4M | $21.7M | ||
| Q3 24 | $164.9M | $11.2M | ||
| Q2 24 | $170.8M | $39.3M | ||
| Q1 24 | $174.4M | $61.6M |
| Q4 25 | $228.4M | $480.2M | ||
| Q3 25 | $224.8M | $506.9M | ||
| Q2 25 | $235.1M | $372.7M | ||
| Q1 25 | $245.8M | $386.7M | ||
| Q4 24 | $251.0M | $392.3M | ||
| Q3 24 | $250.9M | $363.6M | ||
| Q2 24 | $259.0M | $381.8M | ||
| Q1 24 | $269.2M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-25.4M |
| Free Cash FlowOCF − Capex | $-2.2M | — |
| FCF MarginFCF / Revenue | -6.4% | — |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-25.4M | ||
| Q3 25 | $2.5M | $-26.6M | ||
| Q2 25 | $2.6M | $-23.3M | ||
| Q1 25 | $3.4M | $-40.4M | ||
| Q4 24 | $985.0K | $-18.8M | ||
| Q3 24 | $295.0K | $-25.2M | ||
| Q2 24 | $1.4M | $-29.1M | ||
| Q1 24 | $2.1M | $-40.7M |
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $424.0K | — | ||
| Q3 24 | $143.0K | — | ||
| Q2 24 | $898.0K | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | -6.4% | — | ||
| Q3 25 | 6.2% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 2.8% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
